Data from The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema.

Published: 3 February 2022| Version 1 | DOI: 10.17632/j35fzdj7nw.1
Contributor:

Description

The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema. DOI: 10.1038/s41433-020-01373-1

Files

Steps to reproduce

A study to investigate if the visual and anatomic response to the first dexamethasone implant (DEX) predicts the 12-month clinical outcome after shifting to fluocinolone acetonide (FAc) implant in patients with diabetic macular oedema (DMO). this was a retrospective cohort study including pseudophakic patients with previously treated DMO, undergoing one or more DEX injections before FAc. Functional and morphologic response to DEX was defined based on the best-corrected visual acuity (BCVA) and central macular thickness (CMT) changes after the first DEX, respectively. Steroid-response was defined as intraocular pressure (IOP) elevation 5 mmHg or IOP>21 mmHg after any previous DEX exposure. Pairwise comparisons for BCVA, CMT, and IOP after FAc were performed with linear mixed models and a repeated measure design.

Institutions

Ospedale San Raffaele, Universita Vita Salute San Raffaele

Categories

Ophthalmology

Licence